Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of reducing and ultimately eliminating
anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and
replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune
reconstitution and reduce relapse while preserving low rates of graft failure and graft
versus host disease (GVHD).